These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9450614)

  • 1. In vivo homologous regulation of mu-opioid receptor gene expression in the mouse.
    Sehba F; Duttaroy A; Shah S; Chen B; Carroll J; Yoburn BC
    Eur J Pharmacol; 1997 Nov; 339(1):33-41. PubMed ID: 9450614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice.
    Duttaroy A; Yoburn BC
    Synapse; 2000 Aug; 37(2):118-24. PubMed ID: 10881033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
    Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
    Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mu-Opioid receptor downregulation contributes to opioid tolerance in vivo.
    Stafford K; Gomes AB; Shen J; Yoburn BC
    Pharmacol Biochem Behav; 2001; 69(1-2):233-7. PubMed ID: 11420091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo.
    Patel MB; Patel CN; Rajashekara V; Yoburn BC
    Mol Pharmacol; 2002 Dec; 62(6):1464-70. PubMed ID: 12435815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
    Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
    Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
    Zhang Q; Purohit V; Yoburn BC
    Synapse; 2005 Jun; 56(3):123-8. PubMed ID: 15765525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid receptor regulation in mice.
    Yoburn BC; Billings B; Duttaroy A
    J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.
    Gomes BA; Shen J; Stafford K; Patel M; Yoburn BC
    Pharmacol Biochem Behav; 2002 May; 72(1-2):273-8. PubMed ID: 11900797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
    Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
    Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etorphine elicits anomalous excitatory opioid effects on sensory neurons treated with GM1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells.
    Crain SM; Shen KF
    Brain Res; 1996 Nov; 741(1-2):275-83. PubMed ID: 9001733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse.
    Madia PA; Dighe SV; Sirohi S; Walker EA; Yoburn BC
    Psychopharmacology (Berl); 2009 Dec; 207(3):413-22. PubMed ID: 19816677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [(35)S]GTPĪ³S binding and opioid tolerance and efficacy in mouse spinal cord.
    Madia PA; Navani DM; Yoburn BC
    Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus.
    Van Bockstaele EJ; Commons KG
    Neuroscience; 2001; 108(3):467-77. PubMed ID: 11738260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intrinsic efficacy on opioid tolerance.
    Duttaroy A; Yoburn BC
    Anesthesiology; 1995 May; 82(5):1226-36. PubMed ID: 7741298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude.
    Allen RM; Dykstra LA
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1012-21. PubMed ID: 11082436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agonist-specific down regulation of mu-opioid receptors: Different cellular pathways are activated by different opioid agonists.
    Binyaminy B; Gafni M; Shapira M; Sarne Y
    Life Sci; 2008 Apr; 82(15-16):831-9. PubMed ID: 18358497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etorphine increases the number of mu-opioid receptor-positive cells in the cerebral cortex.
    Melone M; Brecha NC; Sternini C; Evans C; Conti F
    Neuroscience; 2000; 100(3):439-43. PubMed ID: 11098106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.